The small apparent difference between receptor binding in vitro and in vivo may result from the relatively poor resolution of PET. No differences in the number of binding sites in left and right brain regions were detected by either PET or in vitro assays. These results provide operational validation for this PET assay of radioligand binding in vivo and demonstrate the lack of right/left differences in striatal SP binding.
We have developed a non-steady-state method for measurement of radioligand binding in vivo using positron emission tomography (PET) and lSF-spiperone (I*F-SP). A three-compartment model that represents the in vivo behavior of an intravenously injected radioligand forms the basis of this assay technique (Mintun et al., 1984; Perlmutteret al., 1986 Perlmutteret al., , 1989 . This method has been used to demonstrate an increase in radioligand binding in a patient with untreated parkinsonism induced by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; Perlmutter et al., 1987) .
Validation of this or any other PET-based measurement of in vivo radioligand binding (Farde et al., 1986 (Farde et al., , 1989 Maziere et al., 1986; Wong et al., 1986a ,b, Eckemas et al., 1987 Logan et al., 1987; Coenen et al., 1988; Frost et al., 1989; Huang et al., 1989; Swart et al., 1990 ) has been a difficult task because of the lack of an appropriate "gold standard." Although there is a vast accumulation of data from experiments that employed in vitro techniques, these results depend heavily upon assay conditions (Seeman et al., 1984) , which clearly differ from the in vivo milieu (Bennett and Wooten, 1986; . Nevertheless, some workers have compared in vitro binding measurements with those derived from in vivo methods (e.g., Farde et al., 1986; Wong et al., 1986b) . This approach can yield interesting information but has limitations, because such comparisons depend upon several crucial assumptions that must be reviewed cautiously.
An alternate approach is to determine the ability of the in vivo PET assay to detect predictable alterations in radioligand binding. In this regard, we previously have demonstrated the sensitivity of our non-steady-state method to a decrease in the apparent maximum number of available specific binding sites (Perlmutter et al., 1989) . That study, however, did not demonstrate the specificity of the in vivo PET assay. Therefore, the purposes of this study are to evaluate the specificity of our PET method and to compare it to that measured with in vitro techniques using the same ligands and animals. We also have investigated potential left/right-brain differences in receptor binding as detected with either assay technique. These results provide a basis for interpreting studies of baboons with unilateral brain lesions.
Materials and Methods
Positron emission tomography. All PET studies were performed with the PETT VI system in the high-resolution mode Yamamoto et al., 1982) . Data were recorded simultaneously for Petlmutter et al. -PET Measurement of i n vivo Receptor Binding seven tomographic "slices" with a center-to-center separation of 14.4 l*F radioactivity were used to calculate the arterial-blood counts due to mm. In-plane (i.e., transverse) reconstructed resolution was about 12 mm in the center of the field of view. and axial resolution was about '*F-SP at any given time.
The free fraction of l*F-SP in blood. f; . was determined for each study 14 mm at the center.
Radioligand. No-carrier-added l*F-SP was prepared as described previously (Perlmutter et al., 1989) . Specific activities determined by HPLC ranged from 1000 to 5000 Ci/mmol at the time of injection. The chemical purity of l*F-SP determined by HPLC showed, in the worst case, a total mass of less than 2 pg SP and less than 2 Mg nitro-SP. The nitro-SP has at least 1 OO-fold lower affinitv for SP bindina sites than SP (Poaun ," using a microfiltration technique (Perlmutter et al., 1989) . These determinations were performed in duplicate or triplicate.
Studies on the same animal were performed at least 3 weeks apart to permit sufficient time for recovery. These experiments were approved by the Animal Studies Committee of the Washington University School of Medicine.
Anatomical placement of regions of interest (ROIs; all 1.1 cm x 1.1 cm in plane), including midline cerebellum, left and right striata, and frontal cortex, was found using proportional measurements and comparisons with a stereotaxic atlas of the baboon brain (Davis and Huffman, 1968; Perlmutter et al., 1989) . This permitted identification of a set of ROIs for a control study (i.e., without pretreatment of unlabeled ligand) for each animal. Once this set of ROIs was established, an automated routine extracted regional measurements from identically placed regions on all sequential PET images collected after injection of l*F-SP. as well as from the CBF and CBV imaaes. The same set of ROIs for each animal was used for all subsequent stcdies in that same animal. et al., 1982) .
Experimentalprocedures. Three to six separate PET studies were done on five different male baboons weighing from 8 to 12 kg. We performed at least two control experiments (i.e., without pretreatment) on each animal. The controls were interspersed among the pretreatment studies for each animal. For each study, the animal was fasted overnight but permitted free access to water until 2 hr prior to the experiment. The animal initially was anesthetized with ketamine (10-15 mg/kg, i.m.), injected with atropine (0.2 mg, i.m.) to decrease secretions, paralyzed with gallamine (24 mg/kg, i.v.), intubated with a soft-cuffed endotracheal tube, and ventilated through a heat and moisture exchanger (Breathaid, BA*l530, Terumo Corporation, Tokyo, Japan) with 70% nitrous oxide and 30% oxygen throughout the study. A 20-gauge plastic catheter was inserted after local anesthesia with lidocaine (1%) into a femoral artery to permit arterial-blood sampling, and a similar catheter was placed into an arm vein for administration of drugs and radiotracers. Blood pressure and pulse were monitored with an intraarterial pressure transducer. Body temperature was monitored with a rectal probe (TeleThermometer, YSI, Yellow Springs, OH) and maintained between 35.5"C and 37.5"C with a heating blanket. Freauent arterial blood gas measurements confirmed that-pC0, and pC0, were constant th;oughout each procedure.
Unlabeled SP (0.2-l mg/kg), ketanserin ( 1 O-25 mg/kg), (-)-sulpiride (5-10 mg/kg), and eticlopride (0.37-4.0 mg/kg) were dissolved in 5 ml of 0.9% saline or lactate-buffered saline. All compounds were from Research Biochemicals Inc. (Natick, MA) and were injected intravenously with careful monitoring of blood pressure and pulse. Unlabeled SP was injected intravenously over 5-l 0 min within 30 min of induction of anesthesia and 3 hr prior to administration of '*F-SP. Ketanserin was administered 1 hr prior to l*F-SP, (-)-sulpiride and eticlopride were injected 2 hr prior to '*F-SP.
The head of the baboon was positioned and secured within the scanner using a modified stereotaxic head holder with mouth and ear bars. A lateral skull radiograph with the position of the PET slices marked by radiopaque wires provided a permanent record of the animal's position within the scanner (Perlmutter et al., 1989) . Both the modified stereotaxic head holder and the lateral skull radiograph permitted precise repositioning of the animals for repeated studies. Attenuation characteristics of the head were determined prior to each study by obtaining a transmission scan with a ring source of 68Ge/68Ga.
For each experiment, regional cerebral blood flow (CBF) was measured using a 40-set PET scan after the intravenous injection of 25-40 mCi H,150 Raichle et al., 1983; Videen et al., 1987) . Regional cerebral blood volume (CBV) was determined following the forced inhalation of 50-85 mCi Cl50 and a 5-min scan (Martin et al.. 1987 : Videen et al.. 1987 . CBF and CBV were measured iust prior to injection of '*F-SP. ' ' _ -At least 3.5 hr after induction of anesthesia, 1.9-16.4 mCi of nocarrier-added l*F-SP (Perlmutter et al., 1989) was injected intravenously over 15 sec. Sequential PET scans were started immediately with the injection and continued repeatedly for 3 hr. Scan durations were 60-120 set initially; longer scans (up to 10 min) were required at the end of the study to maintain coincidence counts above 100,000 per slice. The midpoint (weighted for radioactive decay of I*F) of each scan was recorded as the time elapsed from the start of radioligand injection.
Arterial-blood samples (0.3 ml) were collected every 3-5 set for the first 60-l 20 set after administration of l*F-SP and then with decreasing PETdata analysis. A three-compartment model describing the in vivo behavior of l*F-SP was used to analyze the data from striatal regions, and a two-compartment model (no specific binding of '*F-SP assumed in cerebellum) was used to analyze cerebellar data (Mintun et al., 1984; Perlmutter et.al., 1986 Perlmutter et.al., , 1989 ). -The details of implementation and assumotions of this method have been described (Mintun et al., 1984; Per&utter et al., 1986 Per&utter et al., , 1987 Per&utter et al., , 1989 . Briefly, this method utilizes the following direct measurements: time-dependent regional brain radioactivity, time-dependent concentrations of radioligand and its metabolites in arterial blood, free fraction of radioligand in blood (f,), and regional CBF and CBV. We then estimate the free fraction of radioligand, f* (i.e., the amount free divided by the sum of the free and nonspecifically bound radioligand), in cerebellum and assume that it is the same in striatum. Then, for striatal regions, we estimate the local permeability-surface-area product (PS) for l*F-SP, the apparent combined forward-rate constant (k,'; i.e., the product of the association rate constant of radioligand for specific binding sites and the apparent maximum number of available specific binding sites), and the dissociation rate constant, km,, of radioligand-receptor complex (Perlmutter et al., , 1989 . Parameter estimation was performed as previously described .
Additionally, time-dependent radioactivity measurements for frontal, striatal, and cerebellar regions were compared after decay correction and normalization to the mCi of l*F-SP injected.
In vitro analysis. Animals were killed by injection of pentobarbital (100 mg/kg, i.v.); the brains were quickly removed and dissected, and samples were placed on dry ice and stored at -70°C until further analysis. Membranes were prepared as previously described (Todd and Bauer, 1988) and assayed for )H-spiperone (specific activity, 23-25 Ci/mmol; New England Nuclear) binding in the presence and absence of various unlabeled compounds. Samples (40-100 pg protein) were assayed in triolicate in a total volume of 1 ml that contained 120 mM NaCl. 50 rn& Tris (pH, 7.4), and 0.1-10.0 nM *H-spiperone k 1 PM unlabeled competitor. All incubations were for 15 min at 37°C. Samples were diluted with cold buffer, rapidly collected onto glass-fiber filters, and washed twice more with cold buffer using a modified Brandel cell harvester. Preliminary studies demonstrated that under these conditions *H-spiperone binding displaceable by eticlopride or by ketanserin was saturable, reversible, and maximal by 10-12 min of incubation. The inclusion of l-2 mM CaCl, or 14 mM MgCl, did not affect binding.
The equilibrium binding variables Kd and B,,,, were determined from membrane binding data using the nonlinear curve-fitting program LI-GAND (Munson and Rodbard, 1980) . A constant percent error model ofvariance was assumed. Left/right regional brain values were compared by two-tailed t tests using pooled data.
frequency during the remainder of the study (Perlmutter et al., 1989) . These samoles were counted in an NaI(T1) well-tvoe scintillation countResults er that was cross-calibrated with PETT Vi (Mint; h et al., 1984) . Eleven arterial-blood samples also were analyzed to determine the percentage of total radioactivity present as '*F-SP and as radiolabeled metabolites (Perlmutter et al., 1989) . Each sample was assayed in duplicate, and the mean values for each time point were fit empirically by an equation (Perlmutter et al., 1989) . This equation and the measurements of total Measurements of regional CBF, CBV, and the free fraction of r*F-SP in arterial blood (f,), as well as the estimates of the free fraction in brain tissue (Q and regional PS for i*F-SP, are shown in Tables 1 and 2 . No consistent changes in these variables were found after pretreatment with ketanserin, eticlopride, or unla- Dose refers to intravenous dose (mg/kg) of unlabeled ligand administered prior to 18F-SP. Subject refers to the identity of each baboon (A-E). Regional CBF (ml/se&c) was measured using H,'SO and a 40-set PET scan. Regional CBV (ml/ cc) was measured with CL50 and a 5-min PET scan.
beled SP. Individual changes in these values reflect biological
Estimates of relevant binding variables, including the apparvariability among subjects, biological variability over time withent combined forward-rate constant, k,' (i.e., the product of the in the same subject, and limitations of the reproducibility of association rate constant and the apparent maximum number the PET methodology. Measurements of the fraction of radioof specific binding sites), and the dissociation rate constant, k-,, labeled metabolites of '*F-SP in arterial blood did not change are shown in Table 3 . We found no significant right/left differconsistently after pretreatment with any of the unlabeled ligands. ences by paired t tests in the combined forward-rate constants Table 2 Dose refers to intravenous dose (mgkg) of unlabeled l&and administered prior to '*F-SP. Subject refers to the identity of each baboon (A-E). f; refers to the free fraction of '*F-SP in arterial blood measured by microfiltration techniques. f2 indicates the free fraction of 18F-SP in brain tissue (i.e., the amount free divided by the sum of the nonspecifically bound and free). This is estimated from the PET and arterial-blood data using a two-compartment model applied to the cerebellum. PS is the permeability-surface-area product of the blood-brain barrier for 18F-SP (cckc for a 1 cc tissue volume), calculated as described in Materials and Methods. onstrate that doses of ketanserin greater than 10 mg/kg did not block additional S, binding sites in striatum, because the 0 tissue-activity curves were not shifted downward substantially. Dose refers to intravenous dose (m&g) of unlabeled l&and administered prior to 18F-SP. Subject refers to the identity of each baboon (A-E). Binding values are per cc of brain tissue, expressed as sect. k,' denotes the combined forwardrate constant (the product of the apparent maximum number of specific binding sites and the association rate constant of '*F-SP for those specific sites). k, is the dissociation rate constant of radioligand-receptor complex. Both of these turnover rate constants are estimated from the PET and arterial-blood data using a three-compartment model as described in Materials and Methods. Pretreatment with the S, ligand ketanserin blocked about 35% (left) and 32% (right) of the apparent specific striatal binding of '*F-SP in viva. The lack of substantial changes in the striatal tissue-activity curves for increasing doses of ketanserin demonstrate that the doses employed gave maximum S, receptorblocking effects (Fig. 1) . Furthermore, these doses caused the tissue-activity curves for the S,-rich frontal cortex to appear similar to the cerebellar curves (Fig. 2) . This strongly supports the notion that the doses of ketanserin that were employed were sufficient to block all S, specific binding in vivo in brain tissues.
Pretreatment with the D, ligand eticlopride (2 or 4 mg/kg) blocked 68% (left) and 73% (right) of the apparent specific binding of l*F-SP in vivo in the striata. The higher dose of eticlopride, 4 mg/kg, produced no additional blocking compared to a dose of 2 mg/kg. In contrast, 0.37 mg/kg eticlopride did not block all apparent specific binding sites for '*F-SP (Fig. 3, Table 3 ).
Pretreatment with unlabeled SP (0.2 mg/kg) decreased the estimated combined forward-rate constant of '*F-SP more than either ketanserin or eticlopride (Table 3 ). Higher doses of SP reduce specific binding to a greater extent but, in doing so, do not permit estimation of the combined forward-rate constant due to the low amount of specific binding compared to nonspecifically bound IsF-SP. For example, pretreatment with unlabeled SP (1 mg/kg) reduced the striatal tissue-activity curve to the level of a cerebellar tissue-activity curve, presumably by blocking all specific binding sites in striatum. However, the combined forward-rate constant could not be estimated with confidence.
Sulpiride at an intravenous dose of 5, 8, and 9.6 mg/kg did not cause appreciable change in striatal tissue-activity curves compared to those of controls. Higher intravenous doses of the .t3a
The Journal of Neuroscience, May 1991, 1 f(5) 1395 Figure 2 . Effects of ketanserin on frontal cortex uptake. Decay-corrected measurements of radioactivity in counts per sec/ml/[mCi injected]/[kg body weight] (cpslml/mCi/kg) are shown for frontal cortex and cerebellum of baboons after the intravenous injection of 18F-SP. Three "PreRY' studies (open symbols) were preceded by ketanserin (10-25 mg/kg, i.v.) to block S, receptors. The other two PET studies (solid symbols) were not preceded by ketanserin administration and served as controls. There were no substantial differences among the frontal tissue-activity curves obtained after pretreatment with the three different doses of ketanserin and the control cerebellar tissue-activity curves. These data demonstrate that doses greater than 10 mg/kg of ketanserin block all observable specific S, binding sites in frontal cortex.
ligand caused cardiovascular instability and could not be used safely in baboons.
Interestingly, none of the unlabeled ligands altered the uptake of radioactivity in cerebellum, as demonstrated by a lack of change in tissue-activity curves after pretreatment with eticlopride, ketanserin, or unlabeled spiperone (Fig. 4) . These in vivo results are consistent with the lack of specific binding sites in baboon brain as determined in vitro (Table 4) .
The results of in vitro binding studies closely agreed with the results of in vivo experiments. As shown in Table 4 , binding to D, receptors accounted for about 74% of 3H-SP specific binding in striatum (averaging the B,,,,, data for left and right caudate and putamen). Binding by the radioligand to S, receptors accounted for the remainder. No specific 3H-SP binding in cerebellum was detected. Additionally, there were no significant left/ right differences in Kd or B,,,,, for 3H-SP binding to either D, or S, receptors in these tissues. Given the relatively small number of subjects and the variance in measurements (Table 4) , there was a 75-90% chance to detect at least a 50% difference in B,, but only a 50-80% chance to detect at least a 100% difference in Kd. A summary of nonspecific binding by 'H-SP in vitro is presented in Table 5 . There were no significant differences in nonspecific binding to membranes across brain regions. There were also no significant left/right regional differences in nonspecific binding of 3H-SP.
Discussion
Results of this investigation further validate our non-steadystate technique for measurement of radioligand binding in vivo with PET and 18F-SP. We now have demonstrated the specificity of this in viva assay and compared these results to those of an in vitro binding assay. Furthermore, we also have evaluated the adequacy of the baboon's cerebellum as a region of brain devoid of specific binding sites. This type of operational validation is of in viva Receptor Binding were not preceded by eticlopride administration and served as controls. Pretreatment with 0.37 mg/kg did not appear to maximally block specific binding sites in striatum, whereas 2 and 4 mg/kg of the D, ligand were not substantially different from each other. The "tails" of the tissue-activity curves reflect binding to receptors to a greater degree than the "fronts" of the curves due to clearance of free and nonspecifically bound '*F-SP. necessary because of the lack of a "gold standard" for in vivo binding and requires complete understanding of the methodological issues that impact interpretation of our findings. The specificity of this PET measurement depends not only on the receptor specificity of 18F-SP in vivo, but also upon the resolution of the PET image. In vitro binding studies demonstrated that about 75% of the specific binding of 'H-SP in striaturn was to D, sites, whereas only about 68% of the specific binding in vivo of I*F-SP was blocked by pretreatment with eticlopride. Although the difference may not be statistically significant, it could reflect that the PET measurement of radioactivity from striatum is "contaminated" by inclusion of spillover from nearby temporal cortex, an area that contains S, 3 0 binding sites for 18F-SP that are unaffected by unlabeled eticlopride. This volume averaging (Mazziotta et al., 198 1) may contribute, in part, to the higher apparent S, binding in striatum. Fortunately, such volume averaging from nearby tissues will become less important as the resolution of PET scanners continues to improve (Spinks et al., 1988; Litton et al., 1990 ). An alternate explanation that may contribute to the potential difference between the results from PET and in vitro assays is that in vivo access to specific binding sites is different from that under in vitro assay conditions. Pharmacodynamic factors such as druginduced alterations by ketanserin or eticlopride in radioligand delivery to the striatum are unlikely to cause a change in the measured apparent combined forward-rate constant. This is be- cause our method measures or estimates changes in variables such as regional CBF or regional PS for '*F-SP and incorporates them into the calculation of the apparent combined forwardrate constant. Additionally, the arterial blood content of 18F-SP did not change with the various pretreatment conditions (i.e., metabolism of the radioligand did not change), nor did the free fraction of I*F-SP in blood change. The relatively close values for specificity between the in vivo and in vitro methods are noteworthy.
Another important technical issue of the in vivo PET assay is the degree that S, or D, receptors are blocked competitively by the pretreatment doses of ketanserin or eticlopride. We have shown that the dose of ketanserin that we used caused the tissueactivity curve for the frontal cortex (a region that we found by in vitro assay to contain only S, binding sites for IIF-SP) nearly to overlap the cerebellar curve. Because the cerebellum lacks S, receptors, this result suggests that the dose of the S, ligand that we used blocked all specific binding in vivo by 18F-SP in frontal cortex. Because the frontal cortex has greater $-specific binding than the striatum, it is reasonable to assume, though not absolutely proven, that all striatal S, sites were also blocked. Furthermore, higher doses of ketanserin did not change substantially the striatal or frontal cortex tissue-activity curves for 18F-SP (Figs. 1, 2) . Pretreatment with eticlopride (0.37 mg/kg) did not appear to block all specific striatal binding sites, as demonstrated by the modest lowering of the tissue-activity curves (Fig. 3) and the intermediate decrease in the magnitude of the apparent combined forward-rate constant for 18F-SP (Table 3) . The next-higher dose (2 mg/kg) appeared to block maximally D,-specific binding of 18F-SP in striatum, as evidenced by the lack of substantial change in either the striatal tissue-activity curve (Fig. 3) or the estimated combined forward-rate constant for 18F-SP (Table 3) after pretreatment with 4 mg/kg of the unlabeled ligand. Doses of eticlopride greater than 4 mg/kg were not tolerated by the animals.
As previously discussed (Perlmutter et al., 1989) , we have 144 Figure 4 . Effects of unlabeled ligands on cerebellar uptake. Decay-corrected measurements of radioactivity in counts per sec/ml/[mCi injected]/[kg body weight] (cpslmNmCi/kg) are shown for the cerebellum of baboons after the ilitravenous injection of l*F-SP. Three "PreRx" studies (open symbols) were preceded by intravenous injection of maximal receptor-blocking doses of either eticlopride, ketanserin, or unlabeled SP. The other two PET studies (solid symbols) were not preceded by administration of unlabeled ligands and served as controls. There were no substantial differences among the five tissue-activity curves, which demonstrates that doses of ligands which maximally block available specific binding sites in striatum (Figs. 1,3 ; Table 3) do not block specific binding sites in cerebellum.
chosen to report our values of the combined forward-rate constant as the "apparent forward-rate constant" because of the possible nonequilibrium conditions for the unlabeled ligand (i.e., eticlopride, ketanserin, or SP) during the course of the 18F-SP study. Maximal binding by ketanserin almost certainly has occurred prior to the injection of 18F-SP. This is because of the relatively fast kinetics of intravenously administered ketanserin and eticlopride, as revealed by preliminary data with the radiolabeled ligands (Baron et al., 1985; Kohler et al., 1986; Moerlein and Perlmutter, 1990) .
It should also be noted that the "apparent combined forwardrate constant" and the dissociation rate constant estimated with this PET technique reflect averaged composite values for all specific binding within the ROI. Our data demonstrate that baboon striatum contains S,-and D,-specific binding sites for 18F-SP. The degree to which these two different sites contribute to the binding values that we estimate depends in part upon their availability. After high-dose eticlopride pretreatment, D, sites contribute less (probably none at the higher doses in this study), and the estimated binding constants therefore reflect the characteristics and number of available S, sites. The individual contributions from D, and S, sites are not discernable unless high doses of specific antagonists are used to block binding sites. This could produce undesirable clinical effects in humans and (Todd et al., 1989; O'Malley et al., 1990; Sokoloff et al., 1990) . All of these subtypes bind SP and eticlopride with high affinity and, if present in baboon brain, would have been measured as D, sites in this study. Current pharmacological tools cannot distinguish easily among these receptor subtypes. Messenger RNAs for three individual subtypes can be detected with reverse transcription and DNA amplification (O'Malley et al., 1990; Sokoloff et al., 1990 ). Preliminary studies demonstrate the presence of mRNAs for D2A,,,, D2A,,,, and D, receptor subtypes in baboon basal ganglia (R. D. Todd, unpublished observations) . How the PET-derived variables k,' and km, vary with D, receptor subtypes is unknown. More specific radioligands for PET could help clarify these issues.
It is important to note that the apparent combined forwardrate constant changed in a consistent manner with pretreatment of the primates with the various unlabeled ligands. Other estimated variables, such as the regional PS for l*F-SP and the free fraction in brain tissue, fi, did not change consistently. The dissociation rate constant, k-,, also appears to have increased after pretreatment, though not as consistently as k,'. Interpretation of the change in k-, is more difficult because these estimates are not as reliable as those of k,'. As shown previously (Perlmutter et al., 1989) and confirmed here, the individual estimates (for each parameter estimation) of k,' have an average coefficient of variation of 9.9% (+4.5%), significantly lower (p < 0.00000 1; two-tailed, paired t test) than the average coefficient of variation for k-, (14.2% + 5.0%).
Others have suggested that the cerebellum is not devoid of specific binding sites (Logan et al., 1987; Swart et al., 1990) . Our results do not agree with these conclusions. We found no consistent change in the cerebellar tissue-activity curves after pretreatment with eticlopride, ketanserin, or unlabeled SP. If specific sites were present, large doses of these unlabeled ligands would have diminished the uptake of 18F-SP. Furthermore, there was no consistent alteration in f2 estimated from the cerebellar data. Part of this discrepancy with other previous reports may stem from species variability; the rat may have specific binding sites for SP in the cerebellum (Swart et al., 1990) that are not present in primates. On the other hand, Logan et al. (1987) also studied baboons using PETT VI in the high-resolution mode and found that pretreatment with (+)-butaclamol prior to injection of l*F-SP modestly lowered the cerebellar tissue uptake of radioactivity. It is possible that this finding was due to slight misalignment of the animal within the scanner that caused receptor-rich noncerebellar tissue to be included in the "cerebellar" region. Partial volume averaging from nearby occipital lobe, a region that we found with in vitro analysis to contain S, and D, sites (data not shown), may have contributed to the "apparent specific binding" in cerebellum. We have diminished the effects from nearby occipital lobe by also using the high-resolution mode of PETT VI as well as by careful placement of the animal within the scanner, as previously described (Perlmutter et al., 1989) . Finally, our in vitro data also support our contention based on PET data that cerebellum in baboon contains negligible specific binding sites for SP.
Although all of these lines of evidence strongly support the idea that there is a lack of specific binding of 18F-SP in cerebellum, they do not directly address the issue of a regionally constant f2. In this study, we found that nonspecific binding in vitro was invariant across different brain regions, which suggests that f, is regionally invariant. Nevertheless, it is important to realize that the notions of nonspecific binding for in vitro and in vivo methods may be different. Nonspecific binding as measured in vitro is the residual quantity of radioligand remaining in tissue, either homogenate or slices, after the tissue has been exposed to high concentrations of specific antagonists; that is, it is the amount of nondisplaceable radioligand in this tissue, which may include radioligand entrapped in filters, and so on. This is to be distinguished from the displaceable fraction that reflects specific binding. Nonspecific binding in vivo superficially appears similar. Its definition is that amount of radioligand in a compartment that is not free and not bound to specific binding sites as defined in a compartmental model developed to reflect the in vivo behavior of the radioligand . Operationally in a brain devoid of specific binding sites, the value of the free fraction acts to modify the movement of radioligand from the extravascular space back to the intravascular compartment . Although nonspecific binding for in vitro and in vivo studies appears similar biologically, operationally it may be different depending upon conditions of the assay. Therefore, these in vitro data do not prove that an in vivo fi estimated for 18F-SP in the cerebellum is identical to that in the striatum.
We did not assume that PS for 18F-SP is the same for the cerebellum and the striatum, and values of PS were estimated for each region. Recent data suggest that pial vessels in cerebellum have greater intravascular volume than those in the cerebrum (Holash et al., 1990) . If the PET ROIs included pial vessels within infolded regions of the cerebellum, then the assumption of a regionally constant PS would be inaccurate, because PS estimates are dependent upon regional CBV (Mintun et al., 1984) .
An additional finding of this study (within the limits of statistical power as described in Results) was the lack of left/right differences in specific binding sites in striatum. This was true for both in vivo and in vitro assays and suggests that unilateral lesion studies can use the unperturbed side of a subject as an internal control. Furthermore, these results indicate that sideto-side randomization can be used for control of surgical techniques, without correcting for laterality differences.
This study provides additional operational validation of the non-steady-state measurement of in vivo radioligand binding with PET. Not only has the PET assay performed in a predictable and consistent fashion, but it also gives results that compare closely with those from in vitro binding studies. There was considerable intersubject variability in the estimated apparent combined forward-rate constant (Table 3) , but much less intrasubject variability. Previous studies have demonstrated the sensitivity of this in vivo PET technique to a decrease in the number of apparently available specific binding sites for l*F-SP (Perlmutter et al., 1989) and to an apparent upregulation of specific binding for 18F-SP in a patient with untreated MPTP-induced parkinsonism. Therefore, further investigation with this noninvasive methodology is warranted. Its major limitations continue to be the long duration necessary for each PET study (3-4 hr) and the fact that it estimates the apparent combined forward-rate constant for l*F-SP rather than the maximum number of specific binding sites (B,,,) itself.
